journal article·2013-09

Adenoviral vector tethering to metal surfaces via hydrolyzable cross-linkers for the modulation of vector release and transduction

Ilia Fishbein, Scott P. Forbes, Michael Chorny, Jeanne M. Connolly, Richard F. Adamo, Ricardo A. Corrales, Ivan S. Alferiev, Robert J. Levy

Biomaterials· Volume 34· Issue 28
Publisher page

Abstract

The use of arterial stents and other medical implants as a delivery platform for surface immobilized gene vectors allows for safe and efficient localized expression of therapeutic transgenes. In this study we investigate the use of hydrolyzable cross-linkers with distinct kinetics of hydrolysis for delivery of gene vectors from polyallylamine bisphosphonate-modified metal surfaces. Three cross-linkers with the estimated t1/2 of ester bonds hydrolysis of 5, 12 and 50 days demonstrated a cumulative 20%, 39% and 45% vector release, respectively, after 30 days exposure to physiological buffer at 37 °C. Transgene expression in endothelial and smooth muscles cells transduced with substrate immobilized adenovirus resulted in significantly different expression profiles for each individual cross-linker. Furthermore, immobilization of adenoviral vectors effectively extended their transduction effectiveness beyond the initial phase of release. Transgene expression driven by adenovirus-tethered stents in rat carotid arteries demonstrated that a faster rate of cross-linker hydrolysis resulted in higher expression levels at day 1, which declined by day 8 after stent implantation, while inversely, slower hydrolysis was associated with increased arterial expression at day 8 in comparison with day 1. In conclusion, adjustable release of transduction-competent adenoviral vectors from metallic surfaces can be achieved, both in vitro and in vivo, through surface immobilization of adenoviral vectors using hydrolyzable cross-linkers with structure-specific release kinetics.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Virus-based gene therapy research · RNA Interference and Gene Delivery · Viral Infectious Diseases and Gene Expression in Insects

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (51)

Show source-provided references
1. Immune barriers to successful gene therapy10.1016/j.molmed.2008.11.005 ↗
2. Promoters and control elements: designing expression cassettes for gene therapy10.2174/1566523044578077 ↗
3. Percutaneous methods of vector delivery in preclinical models10.1038/gt.2012.14 ↗
4. Tissue engineering via local gene delivery10.1007/s001090000118 ↗
5. Local gene delivery for cancer therapy10.2174/156652311797415854 ↗
6. Local delivery of matrix metalloproteinase gene prevents the onset of renal sclerosis in streptozotocin-induced diabetic mice10.1089/10763270360728206 ↗
7. Gene therapy for cardiovascular diseases10.2174/1381612043453379 ↗
8. Current status of catheter- and stent-based gene therapy10.1016/j.cardiores.2004.07.003 ↗
9. Site specific gene delivery in the cardiovascular system10.1016/j.jconrel.2005.09.031 ↗
10. Microarrays of cells expressing defined cDNAs10.1038/35075114 ↗
11. Surface immobilization of hexa-histidine-tagged adeno-associated viral vectors for localized gene delivery10.1038/gt.2010.81 ↗
12. Surface-tethered DNA complexes for enhanced gene delivery10.1021/bc015575f ↗
13. Controlled release systems for DNA delivery10.1016/j.ymthe.2004.03.020 ↗
14. Coronary–artery stents10.1056/NEJMra051091 ↗
15. Heart disease and stroke statistics—2011 update: a report from the American Heart Association
16. Coronary artery restenosis: vascular biology and emerging therapeutic strategies10.1586/14779072.4.4.543 ↗
17. Gene therapy for restenosis – what now, what next?10.2174/1566523043346435 ↗
18. Gene therapy for restenosis: biological solution to a biological problem10.1016/j.yjmcc.2006.11.012 ↗
19. Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys10.1161/ATVBAHA.107.154609 ↗
20. Gene delivery from a DNA controlled-release stent in porcine coronary arteries10.1038/81176 ↗
21. Stent-based local delivery of nuclear factor-kappaB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits10.1161/CIRCULATIONAHA.105.582254 ↗
22. DNA delivery from an intravascular stent with a denatured collagen–polylactic–polyglycolic acid-controlled release coating: mechanisms of enhanced transfection10.1038/sj.gt.3302043 ↗
23. Human placental ectonucleoside triphosphate diphosphohydrolase gene transfer via gelatin-coated stents prevents in-stent thrombosis10.1161/ATVBAHA.109.186429 ↗
24. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis10.1161/01.CIR.0000133324.38115.0A ↗
25. Anti-DNA antibody modified coronary stent for plasmid gene delivery: results obtained from a porcine coronary stent model10.1002/jgm.1529 ↗
26. Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents10.1073/pnas.0502945102 ↗
27. Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries10.1161/CIRCULATIONAHA.107.746412 ↗
28. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries10.1161/01.ATV.0000157582.33180.a9 ↗
29. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus10.1089/10430340252792576 ↗
30. Gene-eluting stents: comparison of adenoviral and adeno-associated viral gene delivery to the blood vessel wall in vivo10.1089/hum.2006.17.741 ↗
31. Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis10.1038/mt.2008.165 ↗
32. Gene-eluting stents: non-viral, liposome-based gene delivery of eNOS to the blood vessel wall in vivo results in enhanced endothelialization but does not reduce restenosis in a hypercholesterolemic model10.1038/gt.2011.92 ↗
33. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo10.1089/10430349950018021 ↗
34. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields10.1073/pnas.0909506107 ↗
35. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents10.1073/pnas.0708338105 ↗
36. Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells10.1089/hum.1998.9.3-367 ↗
37. Validation of kinetics similarity in qPCR10.1093/nar/gkr778 ↗
38. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB195410.1002/jgm.795 ↗
39. Tissue engineering of urethra using human vascular endothelial growth factor gene-modified bladder urothelial cells10.1111/j.1525-1594.2007.00502.x ↗
40. The road to biological pacing10.1038/nrcardio.2011.120 ↗
41. Delivery of large biopharmaceuticals from cardiovascular stents: a review10.1021/bm700540p ↗
42. Release of plasmid DNA from intravascular stents coated with ultrathin multilayered polyelectrolyte films10.1021/bm0604808 ↗
43. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model10.1016/j.cardiores.2004.04.029 ↗
44. Rat arterial wall retains myointimal hyperplastic potential long after arterial injury10.1161/01.CIR.96.4.1291 ↗
45. Transgene delivery of plasmid DNA to smooth muscle cells and macrophages from a biostable polymer-coated stent10.1038/sj.gt.3302010 ↗
46. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries10.1161/01.CIR.94.7.1690 ↗
47. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions10.1089/10430340050111368 ↗
48. Inflammation and restenosis in the stent era10.1161/01.ATV.0000037100.44766.5B ↗
49. Interpretation of protein adsorption: surface-induced conformational changes10.1021/ja042898o ↗
50. Biocompatibility of cardiovascular gene delivery catheters with adenovirus vectors: an important determinant of the efficiency of cardiovascular gene transfer10.1006/mthe.2000.0059 ↗
51. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities10.1016/S0169-409X(02)00179-5 ↗